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Abstract
Optimising non-viral vectors for neuronal siRNA delivery presents a significant challenge. Here, we investigate a co-
formulation, consisting of two amphiphilic cyclodextrins (CDs), one cationic and the other PEGylated, which were blended
together for siRNA delivery to a neuronal cell culture model. Co-formulated CD-siRNA complexes were characterised in
terms of size, charge and morphology. Stability in salt and serum was also examined. Uptake was determined by flow
cytometry and toxicity was measured by MTT assay. Knockdown of a luciferase reporter gene was used as a measure of
gene silencing efficiency. Incorporation of a PEGylated CD in the formulation had significant effects on the physical and
biological properties of CD.siRNA complexes. Co-formulated complexes exhibited a lower surface charge and greater
stability in a high salt environment. However, the inclusion of the PEGylated CD also dramatically reduced gene silencing
efficiency due to its effects on neuronal uptake. The co-formulation strategy for cationic and PEGylated CDs improved the
stability of the CD.siRNA delivery systems, although knockdown efficiency was impaired. Future work will focus on the
addition of targeting ligands to the co-formulated complexes to restore transfection capabilities.
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Introduction
Silencing of genes using RNA interference (RNAi) based
technology is one of the most exciting areas of research in modern
molecular medicine [1–3]. Progression of RNAi towards in vivo use
requires a greater focus on overcoming the stability and targeting
issues associated with cationic siRNA delivery vectors [4], [5]. In
particular, improving delivery of siRNA to neurons and the CNS
remains a challenge [6], [7].
Cyclodextrins (CDs) modified with various amphiphilic and
cationic groups offer great potential as non-viral gene and siRNA
delivery vectors [8–10]. Indeed, we have shown successful gene
delivery by modified b-CDs to a variety of cell types including liver
cells and intestinal epithelial cells and to in vitro and in vivo tumour
models [11–15]. A recent development in the modification of CDs
is the ‘click’ chemistry based synthesis of a cationic amphiphilic
CD, SC12CDClickpropylamine (Fig. 1 (a)) [16]. This CD was
effective at mediating siRNA delivery in non-neuronal cells [16]
and neuronal cells [17], [18].
An interesting strategy for the optimisation of non-viral vector
delivery systems is the ‘ABCD’ nanoparticle concept by Kostarelos
and Miller [19]. Here, ‘A’ represents the nucleic acid cargo, ‘B’
represents the component which complexes the nucleic acid, ‘C’ is
a stabilising component and ‘D’ is a targeting moiety. Typically,
‘C’ is a polyethyleneglycol (PEG) component, which acts as a steric
shield to prevent interaction with plasma proteins, inhibits uptake
by the reticulo-endothelial system, improves stability in biological
fluids and minimises the toxicity associated with cationic vectors
[20–22]. The aforementioned cationic click CD-siRNA formula-
tion, effective at mediating transfection in neurons [17], fits the
‘AB’ paradigm. Therefore, to improve this formulation for in vivo
use, further modifications, including PEGylation, are required.
Commonly used strategies for developing PEGylated nucleic
acid vectors include post-insertion of PEGylated lipids into
preformed lipoplexes [23] or lipid nanocapsules [24], grafting of
PEG chains onto cationic polymers [20], [21] or addition of a
PEGylated polymer to pre-formed polymer-siRNA complexes
[25]. siRNA itself has also been directly conjugated with PEG
chains before complexation by a cationic peptide [26] or
LipofectamineTM 2000 [27] with improvements reported in
nuclease stability and immunogenicity, whilst maintaining gene
silencing efficiency. Yet another strategy for PEGylation is the
mixing of a cationic component with its PEGylated counterpart in
a formulation, before complexation of siRNA. This approach has
been exploited for both polymeric [22] and lipidic [28] vectors.
Regarding CD-based fomulation strategies, the most widely
used approach for PEGylation exploits their ability to form an
inclusion complex with guest molecules such as adamantane, via
the hydrophobic cavity of the CD molecule [29]. Using this
mechanism, PEG chains, chemically linked to adamantane, have
been incorporated into CD-containing vectors such as chitosan-
PEI-b CD copolymers [30] or cationic CD-containing polymers
(CDP) [29], [31]. In another approach, we have reported
modifying pre-formed CD.siRNA complexes at their surface by
inclusion of a lipid-PEG conjugate in the formulation [32].
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Direct modification of the CD structure with PEG chains has
proved more challenging. Early approaches by our group included
attachment of short oligo(ethylene oxide) moieties at the 2-
positions by base-catalysed reaction with ethylene carbonate [11],
[33], but this synthesis was not amenable to attachment of longer
PEG chain lengths. The recently developed copper-catalysed
‘click’ chemistry approach used for modifying CDs has facilitated
selective attachment of PEG chains to the 2-position of an
amphiphilic CD [16]. The structure of the resulting PEGylated
amphiphilic CD is illustrated in Fig. 1 (b). Hydrocarbon group
C12 was chosen based on previous work showing that increasing
the chain length of amphiphilic CDs improves transfection
efficiency [11], [12], while PEG MW 500 was chosen based on
the potential for immunogenicity with higher PEG MW [50].
Previously, we reported preliminary efforts to blend the cationic
and PEGylated CDs together in a co-formulation [16]. The PEG
containing formulations exhibited altered properties including
greater salt-stability but also a lack of gene silencing efficiency,
compared to the cationic CD alone [16].
Delivery of siRNA to neurons is particularly challenging, due to
their post-mitotic nature and complexity of neuronal networking
[6], [34]. Indeed, we found that for the aforementioned cationic
CD, SC12CDClickpropylamine, a higher mass ratio of 20 was
required to achieve adequate gene silencing in neuronal cells [17],
compared to MR 10, which was sufficient in non-neuronal cells
[16]. Using MR 20 CD complexes, knockdown of housekeeping
and reporter genes (40–60%) was achieved in primary and
immortalised neurons, with minimal toxicity compared to
LipofectamineTM 2000 [17].
Here, as part of our efforts towards developing a PEG-stabilised
CD vector for neurons and the CNS, we again applied a co-
formulation approach, based on the higher MR complexes. To
this end, we investigated the effects of PEGylation in the context of
neuronal siRNA delivery, in terms of uptake, neuronal viability
and knockdown efficiency. Furthermore, we carried out a detailed
characterisation of the co-formulated complexes, including the
effects of the PEG component on complex morphology and on the
serum-induced aggregation.
SC12CDClickpropylamine and SC12CDClickPEG 500 will be
referred to hereafter as cationic CD and PEGylated CD
respectively.
Materials and Methods
Preparation of Vector.siRNA Complexes
siRNAs. Negative control (non-silencing: ns) siRNA (sense
sequence 59- UUC UCC GA CGU GUC ACG U), fluorescein
labelled siRNA (sense sequence 59- UUC UCC GAA CGU GUC
ACG U, modified with 39-fluorescein on the sense strand), pGL3
luciferase siRNA (sense sequence 59- CUU ACG CUG AGU
UCG A) and GAPDH siRNA (sense 59- GGU CGG UGU GAA
CGG AUU U) were obtained from Qiagen (California, USA).
CD.siRNA complexes. CD.siRNA complexes were pre-
pared as before [16]. Briefly, the two CDs were weighed out
and dissolved in chloroform (1 mg/ml), then mixed together in
appropriate volumes to give required molar ratios of cationic to
PEGylated CD. The solvent was removed with a gentle stream of
nitrogen. Aliquots were stored at 220uC until required. For
preparation of CD.siRNA complexes, CDs were rehydrated with
deionised water (DIW) (final concentration 1 mg/ml), sonicated for
one hour at room temperature (RT), mixed with siRNA in an
equal volume of water and incubated for 20–30 min at RT. For all
experiments, a fixed cationic CD:siRNA MR of 20 was chosen,
based on previous results [17]. All formulations, irrespective of the
amount of PEGylated CD incorporated, contained the same
proportion of cationic CD to siRNA.
Figure 1. Chemical structures and properties of CDs and complexes. (a, b) Chemical structures and schematic representations of Cationic CD
(a) and PEGylated CD (n = 10–12) (b). (c) Gel electrophoresis showing siRNA binding within co-formulated CD.siRNA complexes. (d) Size (Z-Ave (nm),
black bars) and charge (zeta potential (mV), grey square boxes) of co-formulated CD.siRNA complexes. Data are presented as the Mean 6 S.D (n = 3).
doi:10.1371/journal.pone.0066413.g001
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Gel Retardation Assay
siRNA binding was investigated by agarose gel electrophoresis
[21]. CD.siRNA complexes were mixed with loading buffer and
DIW to a final volume of 20 ml (containing 0.3 mg siRNA).
Samples were added to wells in a 1% agarose gel containing
SafeViewTM (NBS Biologicals Ltd, England) (6 ml/100 mls).
Electrophoresis was carried out at 90 V for 20 minutes, with a
Tris-borate-EDTA buffer [35]. Bands corresponding to the DNA
ladder (100 b.p.) and unbound siRNA were visualised by UV,
using the DNR Bioimaging Systems MiniBis Pro and Gel Capture
US B2 software.
Size and Charge Measurements
Particle Z-average size and charge were measured with
Malvern’s Zetasizer Nano ZS, using dynamic light scattering
(DLS) and electrophoretic mobility measurements respectively.
CD.siRNA complexes were prepared and made up to 1 ml with
0.2 mm filtered DIW. Five readings of Z-average size (nm),
polydispersity (25uC, measurement angle 170u) and zeta potential
(mV) (25uC, measurement angle 12.8u) were taken. For data
analysis, the viscosity (0.8872 mPa.s) and refractive index (1.33) of
water were used to determine Z-average size.
Morphology of CD.siRNA Complexes
The morphologies of CD.siRNA complexes were evaluated
using transmission electron microscopy (TEM) as previously
described [15], [33], [36]. Briefly, cationic CD alone and
CD.siRNA complexes (containing 0.5 mg siRNA) were applied
to 400 mesh carbon-film copper grids (Agar Scientific) for a couple
of minutes. The grids were blotted with filter paper, stained with
2% (w/w) uranyl acetate and incubated overnight. Images were
taken using a JEOL 2000 FXII transmission electron microscope
(Jel Ltd., Tokyo, Japan).
Aggregation Studies
The effects of salt-containing medium and serum on the
aggregation of the co-formulated CD.siRNA complexes were
investigated by incubating complexes in either OptiMEMH
transfection medium or foetal bovine serum (FBS) for 24 hours
at 37uC [21], [32]. Following this, size measurements were carried
out by DLS.
Cell Culture
A mouse embryonic hypothalamic cell line (mHypoE N41) [37]
was obtained from tebu-bio (France) and was maintained in
Dulbecco’s modified Eagle’s medium (DMEM, Sigma), supple-
mented with 10% foetal bovine serum (FBS, Sigma) in a
humidified 37uC incubator with 5% CO2. Cells were seeded in
24 well and 96 well plates at 3.56104 and 1.56104 cells per well
respectively. This cell line is a useful model for neuronal cells [17].
Determination of Cell Viability
Cell viability in terms of mitochondrial dehydrogenase activity
was determined by the MTT assay [15], [21]. Cells were seeded in
96-well plates 1 day prior to transfection. siRNA (50 and 100 nM)
alone, or in CD.siRNA complexes, was diluted in OptiMEMH,
then added to cells in serum-containing medium for 24 h. Media
was removed and replaced with 100 ml fresh media and MTT
(20 ml of a 5 mg/ml solution) for four hours, after which the
formazon crystals produced were dissolved in 100 ml DMSO.
Absorbance was measured at 590 nm using a UV plate reader.
Each experiment was carried out in triplicate. Results were
expressed as % cell viability compared to untreated controls.
Cellular Uptake Experiments
The level of uptake mediated by transfection complexes was
assessed by flow cytometry [38]. Fluorescently labelled siRNA
(Qiagen) was used for these experiments. Cells were seeded in 24-
well plates 1 day prior to transfection. siRNA (50 nM) alone, or in
CD.siRNA complexes, was diluted in OptiMEMH and applied to
cells in serum-containing medium for 24 hours. Following this,
complexes bound to the extracellular surfaces were removed by
washing cells with PBS and by incubation with 250 ml of
CellScrub buffer for 15 minutes at room temperature [21]. Cells
were removed from the wells and prepared for analysis following
several washing steps. The fluorescence associated with 10,000
cells was measured with a FACS Caliber instrument (BD
Biosciences) and data was analysed using Cell Quest Pro software.
Each experiment was carried out in triplicate.
Knockdown of Luciferase Reporter Gene
Silencing of an exogenous gene was assessed by measuring
knockdown of a luciferase reporter plasmid [17]. The pGL3-luc
plasmid contains the firefly luciferase gene under the control of an
upstream SV40 promoter [21]. Cells were seeded in 24-well plates
1 day prior to transfection, then transfected with pGL3-luciferase
(1 mg/well) complexed to Lf2000 (2.5 ml/ mg pDNA), for three
hours. Cells were washed twice with PBS prior to siRNA
transfection. pGL3-luciferase siRNA (50 nM) alone, or in
CD.siRNA complexes, was diluted in OptiMEMH and added to
the cells in serum-containing medium. CD.siRNA complexes with
negative control siRNA (ns siRNA) were included as controls.
After 24 hours, cells were washed with PBS, lysed with 400 ml of
16Reporter Lysis Buffer (Promega) and frozen at 280uC. Lysate
was collected and centrifuged for 5 min at 13000 rpm. A sample
of the supernatant (20 ml) was assayed for expression of luciferase
by adding to 100 ml of luciferin (Promega) and measuring the light
(relative luminescence units (RLU)) produced 10 seconds later in a
Junior LB 9059 luminometer (Promega). Total protein levels in
each sample were determined by the BCA Protein Assay (Thermo
Scientific) to allow normalisation of luciferase activity (RLU per mg
protein). Results were expressed as % gene expression relative to
‘untreated’ control samples (which were transfected with luciferase
plasmid only but no siRNA and which were thus assigned as 100%
luciferase expression). Each experiment was carried out in
triplicate.
Statistics
One-way analysis of variance (ANOVA) was used to compare
multiple groups followed by Bonferroni’s post hoc test. Statistical
significance was set at *p , 0.05.
Results
Co-formulated cationic and PEGylated CD.siRNA complexes
were prepared as described in the methods, whereby the two CDs
were mixed together in appropriate amounts, prior to complex-
ation of siRNA. The mass ratio (MR) of cationic CD to siRNA was
kept constant at MR 20. The amount of PEGylated CD in the CD
formulation was varied and was expressed as molar ratio of
cationic CD to PEGylated CD. For example, molar ratio 1:0
represents the cationic CD alone, whereas molar ratio 1:1
represents the formulation with the greatest proportion of
PEGylated CD relative to cationic CD.
Cyclodextrin Co-Formulations for siRNA Delivery
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Effect of PEGylation on siRNA Complexation and Size and
Charge
Co-formulated CD.siRNA complexes were analysed by agarose
gel electrophoresis to determine the binding of siRNA (Fig. 1(c)). A
band was observed only in the lane corresponding to free siRNA,
confirming that the co-formulated complexes were still capable of
binding siRNA to the same extent as the cationic CD alone (1:0).
To investigate the effects of the PEGylated CD on the size and
charge, co-formulated CD.siRNA complexes were prepared and
their sizes and charges in water were measured using the Malvern
ZetaSizer Nano. Complex sizes decreased with the inclusion of
PEGylated CD, from 120 6 2.1 nm at molar ratio 1:0 to 91 6
2.8 nm at 10:1 (Fig. 1 (d)), a finding which is in agreement with our
previously published work based on co-formulated complexes at
MR 10 [16]. Samples at molar ratio 1:1 had a PDI of . 0.5, which
indicates considerable variation in particle size and these samples
were, therefore, excluded from particle size analysis.
Surface charge of complexes also decreased with increasing
amounts of PEGylated CD (Fig. 1 (d)), as expected from our
previous work [16]. The highly positive charge of the cationic CD
alone (+ 47.6 6 0.5 mV) was reduced to ,30 mV at molar ratio
100:1. However, there was no greater decrease in surface charge
with increasing proportions of PEGylated CD.
Morphology of CD.siRNA Complexes
The morphologies of CD.siRNA complexes were investigated
by TEM, with and without PEGylated CD in the formulation.
Generally, the cationic CD (Fig. 2(a)) and its corresponding
CD.siRNA complex (Fig. 2(b)) gave irregular shaped particles of
100 – 150 nm in diameter, confirming the particle size measured
by DLS. In addition, an irregular looped pattern was observed for
CD.siRNA complexes, which was not seen for CD alone. A similar
pattern was observed previously for cationic lipid-siRNA lipo-
plexes [39]. There, a more regular lamellar pattern was shown for
some of the lipids investigated, while others gave a pattern which
closely resembled that obtained here for the CD.siRNA complex-
es. For CDplexes with plasmid DNA, a lamellar pattern of
alternating DNA and CD layers was previously reported [40].
By comparison, when PEGylated CD was included at molar
ratio 1:1, a dramatic change in the particle morphologies was
observed (Fig. 2 (c)), with a distinct ‘shielding’ layer visible around
the particles. Moreover, a heterogeneous population made up of
Figure 2. Morphology of CD.siRNA complexes assessed by transmission electron microscopy. (a) Cationic CD alone with no siRNA
(magnification: x 60,000) (b) Cationic CD: PEGylated CD Molar ratio 1:0 (i.e. no PEG) (magnification: x 250,000) and (c) Cationic CD: PEGylated CD Molar
ratio 1:1 (magnification: x 60,000). (Negative staining with 2% uranyl acetate).
doi:10.1371/journal.pone.0066413.g002
Cyclodextrin Co-Formulations for siRNA Delivery
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individual particles and clusters of particles was evident, confirm-
ing the polydisperse nature of this sample.
Salt- and Serum-induced Aggregation of CD.siRNA
Complexes
The conditions to which complexes are exposed in vitro or in vivo
consist of a high salt and serum containing environment [15], [21].
Incorporation of PEG groups into a formulation can confer
stability to nanoparticles against salt-induced aggregation and
non-specific binding of proteins [41]. Therefore, to investigate
these factors, CD.siRNA complexes were incubated with either
OptiMEMH (serum-free transfection media containing physiolog-
ical salt concentrations) or FBS at 37 uC, before measuring particle
sizes.
CD.siRNA complexes with little or no PEGylated CD in the
formulation had the greatest tendency to aggregate in a salt-
environment (OptiMEMH) (Fig. 3 (a) and (b)). After four hours
incubation, there was a doubling in size of cationic CD.siRNA
complexes (Fig. 3 (a)) and after twenty-four hours incubation, large
aggregates were present (Fig. 3 (b)). However, those CD.siRNA
complexes with PEGylated CD in the formulation showed a
marked resistance to aggregation, in particular at molar ratios 10:1
and 1:1. This indicates that the PEG component stabilised the
complexes and inhibited salt-induced aggregation.
Sizes of CD.siRNA complexes, after incubation in 90% FBS for
twenty-four hours, were also investigated. Particle size distribution
data generated from DLS measurements demonstrated that
significant aggregation occurred when CD.siRNA complexes were
incubated in serum, either when the cationic CD was used alone
(Fig. 3 (c)) or when the PEGylated CD was included in the
formulation (Fig. 3 (d)). This indicates that the PEGylated CD did
not stabilise the complexes against non-specific binding of protein
[32].
Effect of PEGylation on Uptake and Gene Silencing
Efficiency of CD.siRNA Complexes
Fluorescently-labelled siRNA was used to study the uptake of
CD.siRNA complexes by neuronal cells, using flow cytometry.
High levels of uptake were mediated by the cationic CD.siRNA
complexes (i.e. molar ratio 1:0, no PEGylated CD) (Fig. 4 (a)).
However, inclusion of the PEGylated CD in the formulation
significantly reduced uptake, at all molar ratios (#p , 0.05
compared to 1:0 CD.siRNA complexes). Uptake was reduced to,
30% at the lowest molar ratio (200:1). A further decrease to ,
12% was observed at molar ratio 1:1. There was no evidence of
internalisation of naked siRNA.
The ability of CD.siRNA complexes to deliver functional
siRNA for RNAi was assessed by using luciferase siRNA to silence
pGL3 luciferase plasmid expression in neuronal cells. Using
50 nM siRNA, the cationic CD.siRNA complexes (1:0) achieved a
significant reduction in luciferase expression (*p , 0.05 relative to
untreated controls), which was comparable to that obtained with
LipofectamineTM 2000 (Fig. 4 (b)). However, inclusion of
PEGylated CD completely abolished the gene silencing capabil-
ities of CD.siRNA complexes. Cationic CD complexes containing
Figure 3. Stability of co-formulated CD.siRNA complexes. Particle size of complexes after incubation in (a, b) OptiMEMH or (c, d) 90% FBS. (a)
and (b) depict 4 and 24 hours respectively. (c) and (d) depict co-formulated CD.siRNA complexes at molar ratios 1:0 and 10:1 respectively.
doi:10.1371/journal.pone.0066413.g003
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a control non-silencing siRNA sequence (1:0/ns) did not affect
luciferase expression, confirming specificity of gene knockdown.
Effect of PEGylation on Toxicity of CD.siRNA Complexes
Modification of cationic particles with PEG groups can improve
their toxicity profile and, to investigate this, the viability of
neuronal cells after 24 hours of treatment with CD.siRNA
complexes (50 and 100 nM siRNA), with and without PEGylated
CD, was determined by MTT assay. We have previously shown
that 100 nM siRNA is required for knockdown of an endogenous
housekeeping gene and, therefore, it was important to consider the
toxicity of the PEGylated complexes at this higher siRNA
concentration [17]. Treatment with cationic CD.siRNA complex-
es or with mixed CD.siRNA complexes cause minimal toxicity to
neuronal cells (Fig. 5). However, at the highest molar ratio (1:1)
and siRNA concentration 100 nM, there was a significant
reduction in cell viability (Fig. 5(b), 68 6 2.2 %, * p , 0.05
relative to untreated cells). It is worth noting that, with the
exception of the 1:1 formulation, the levels of toxicity observed
here were minimal compared to those obtained with Lipofecta-
mine 2000 (67 6 4%) in our previous studies [17].
Discussion
We have previously shown that a modified CD, SC12CDClick-
propylamine, was an effective vector for siRNA delivery to
neurons [17]. However, due to its cationic nature, this CD is likely
to aggregate in the circulation, thereby minimising access to the
CNS. Therefore, efforts to improve the formulation towards more
favourable properties for in vivo use are described here. A co-
formulation approach, which involved blending the cationic CD
with a PEGylated CD of similar amphiphilicity, was previously
investigated in non-neuronal cells (Caco2 cells), for which a lower
cationic CD to siRNA MR of 10 was efficient at mediating gene
silencing [16]. However, higher MR complexes (MR 20) are
required for effective transfection and gene knockdown in neurons
[17]. Therefore, we investigated whether the co-formulation
approach could be applied to neuronal cells, which are notoriously
resistant to transfection and susceptible to the cytotoxic effects of
cationic vectors [6], [42].
By applying the ‘ABCD’ structural paradigm for non-viral gene
delivery vectors, improved stability and specificity can be achieved
by the introduction of additional components such as PEG and/or
targeting ligands [19]. Here, we describe ‘ABC’ type nanoparti-
Figure 4. Internalisation and transfection of neuronal cells by CDs. (a) Uptake and (b) Gene knockdown by CD.siRNA complexes in mHypoE
N41 cells by co-formulated CD.siRNA complexes (siRNA 50 nM). (a) Complexes were applied for 24 hours before measuring uptake by flow cytometry.
Uptake was expressed as percentage of fluorescent siRNA positive cells. (b) Cells were incubated with pGL3-luc complexed to Lf2000 for 3 hours, then
CD.siRNA complexes were applied for 24 hours before assessing for luciferase expression. Luciferase expression was calculated as a percentage of
untreated cells. Data are presented as mean 6 SEM (n= 3). * p , 0.05 relative to untreated cells. (1:0/ns contains non-silencing siRNA and is included
as a control).
doi:10.1371/journal.pone.0066413.g004
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cles, achieved by co-formulating the PEGylated CD (‘C’) with the
cationic CD (‘B’) before complexation of siRNA (‘A’), an approach
described as ‘pre modification’ [19]. These CDs are compatible in
a co-formulation, due to their similar amphiphilicity and this
strategy precludes the requirement for additional non-CD based
components. The co-formulated CD mixture retained its ability to
complex siRNA, as shown in Figure 1 (c). Furthermore, inclusion
of the PEGylated CD in the formulation led to a smaller particle
size (Fig. 1(d)), as previously reported with other vectors [22], [25]
as well as a reduction in surface charge, which was in agreement
with our previously studied low MR co-formulation [16]. Changes
to the morphologies of CD.siRNA complexes were also apparent
(Fig. 2), giving further evidence to successful modification of the
complexes with the PEG component.
Furthermore, the PEGylated CD had a dramatic effect on
complex stability in the presence of salt-containing medium
(OptiMEMH), with little aggregation observed in the 10:1 co-
formulated complexes, even after 24 hours incubation (Fig. 3 (a)
and (b)). This is indicative of a PEG layer at the surface of the
complexes [30] and is in agreement with previously published data
regarding PEGylated CD formulations [16], [32]. However, the
PEG component was not sufficient to prevent interaction with
serum proteins as evidenced by the large aggregates formed when
complexes were incubated for 24 hours in FBS (Fig. 3 (c) and (d)).
Although cationic nanoparticles are likely to aggregate due to non-
specific interaction with negatively charged proteins, incorporation
of a PEG component can prevent these interactions and inhibit
aggregation [21], [22]. However, in this instance the lack of
effectiveness of the PEGylated CD may be due to the relatively low
molecular weight of the PEG (500 Da). Indeed, in another study
where we modified the surface of CD.siRNA complexes with a
lipid-PEG2000 conjugate, aggregation in serum-containing medi-
um was also observed, indicating that even higher PEG molecular
weights of up to 5000 Da may be needed for ‘stealth’ effects [30].
Another reason for the inclusion of a PEG component is to
improve the toxicity profile of the vector [21], [22]. Cationic
vectors are known to cause significant toxicity, particularly to
neuronal cells [43–45]. Here, both cationic and co-formulated
complexes caused minimal toxicity, with high levels of cell viability
even after 24 hours. However, a significant reduction in cell
viability was seen for the co-formulated complexes at the highest
molar ratio (1:1) (Fig. 5 (b)). This may be due to the presence of
some aggregates in this sample (high PDI). However, it is worth
noting that the reduction in cell viability to , 70% is comparable
to that seen after treatment with the widely used commercial
vector LipofectamineH 2000 [17].
The incorporation of a PEG shielding layer seemed to impair
interaction with the cell membrane and subsequent uptake, given
that the levels of intracellular siRNA mediated by the co-
formulated complexes were significantly lower than those obtained
with the cationic CD alone (Fig. 4 (a)). Furthermore, the
PEGylated CD had a dramatic effect on gene silencing efficiency,
with no significant knockdown achieved even with the least
amount of PEGylated CD in the formulation (Fig. 4 (b)), as was
previously shown in non-neuronal cells (Caco2) [16]. Varying
effects of PEGylation on gene knockdown have been reported by
other groups, with some reporting a lack of gene silencing with a
PEGylated vector [46] and others reporting highly efficient gene
silencing with a PEG component in the formulation [25], [30]. In
a previous study, where CD.siRNA complexes were surface
modified with lipid-PEG-octaarginine, uptake levels and gene
silencing were maintained compared to the unmodified complex-
es, likely due to the inclusion of the cell-penetrating peptide [32].
Therefore, it is clear that the effects of PEGylation on transfection
depend on the vector, the PEG linker and the presence of a
targeting ligand. In the current study, addition of the PEGylated
CD impaired gene silencing which may be due, at least in part, to
the reduction in uptake compared to the cationic CD alone.
However, the levels of uptake were still greater than those
achieved for naked siRNA and so other factors, such as impaired
endosomal escape or intracellular release of the nucleic acid cargo,
may also play a role [47].
Overall, given the higher toxicity of the 1:1 formulation and its
high polydispersity and heterogeneous size range in water, the
formulation containing 10:1 cationic CD to PEGylated CD may
be more suitable for future development as a neuronal delivery
vector. In order to fully optimise stability for in vivo use, co-
formulations consisting of higher MW PEGylated CDs with a
cationic counterpart warrant investigation, with a view to
optimising stability in the circulation. Furthermore, the approach
outlined here lends itself to the development of a CD-based
formulation made specific for neuronal and CNS delivery by the
attachment of a targeting ligand, such as transferrin or the RVG
peptide [48], [49], via the PEG chains (‘ABCD’ type formulation).
Such modifications can be facilitated by further advances in this
type of CD technology.
Conclusions
Here, we show that co-formulation is a successful approach for
modifying CD-based siRNA delivery vectors for neurons. Com-
plexes were investigated at MR20, as required for adequate
Figure 5. Neuronal viability after treatment with CDs. Viability of
mHypoE N41 neuronal cells after treatment with CD.siRNA complexes
(MR 20 cationic CD:siRNA) for 24 hours, with increasing content of
PEGylated CD in the formulation, (a) 50 nM siRNA and (b) 100 nM
siRNA. Cell viability was measured by means of MTT assay. Data are
expressed as mean 6 SEM (n= 3).
doi:10.1371/journal.pone.0066413.g005
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neuronal siRNA transfection. Incorporation of the PEGylated CD
into the formulation reduced the surface charge and improved the
stability in a salt-environment, although it was not sufficient to
confer serum-stability. In addition, PEGylation mediated signifi-
cant effects on neuronal uptake and gene silencing, both of which
were reduced due to the steric shielding effects of the PEG chains.
This represents a step towards the development of a neuron-
specific siRNA delivery vector, with enhances stability properties
for future in vivo use.
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